UniProtKB/Swiss-Prot P07949 : Variant p.Ser690Pro
Proto-oncogene tyrosine-protein kinase receptor Ret
Gene: RET
Feedback ?
Variant information
Variant position:
690
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Serine (S) to Proline (P) at position 690 (S690P, p.Ser690Pro).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from small size and polar (S) to medium size and hydrophobic (P)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In HSCR1; sporadic form.
Any additional useful information about the variant.
Sequence information
Variant position:
690
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
1114
The length of the canonical sequence.
Location on the sequence:
SSAEMTFRRPAQAFPVSYSS
S GARRPSLDSMENQVSVDAFK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human SSAEMTFRRPAQAFPVSYSSS GARRPSLDSMENQVSVDAFK
Mouse ASAEMTFCRPAQGFPISYSSS GTRRPSLDSTENQVPVDSFK
Rat ASAEMTFCRPAQGFPISYSSS GTRRPSLDSMENQVSVDSFK
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
29 – 1114
Proto-oncogene tyrosine-protein kinase receptor Ret
Chain
29 – 707
Extracellular cell-membrane anchored RET cadherin 120 kDa fragment
Topological domain
658 – 1114
Cytoplasmic
Modified residue
687 – 687
Phosphotyrosine; by autocatalysis
Modified residue
696 – 696
Phosphoserine
Glycosylation
688 – 688
O-linked (GlcNAc) serine
Mutagenesis
707 – 707
D -> N. Impaired cleavage by caspase-3 and loss of induced cell death.
Literature citations
Japanese patients with sporadic Hirschsprung: mutation analysis of the receptor tyrosine kinase proto-oncogene, endothelin-B receptor, endothelin-3, glial cell line-derived neurotrophic factor and neurturin genes: a comparison with similar studies.
Sakai T.; Nirasawa Y.; Itoh Y.; Wakizaka A.;
Eur. J. Pediatr. 159:160-167(2000)
Cited for: VARIANTS HSCR1 GLN-287; PRO-690; ARG-767 AND GLN-873;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.